格列美脲治療2型糖尿病有效性及安全性系統評價_《中國循證醫學雜志》

作者：

柳汝明 ^1,2 , 賈萍 ³ , 唐堯 ¹

1. 四川大學華西醫院藥劑科（成都 610041）；2. 四川大學華西藥學院（成都 610041）；3. 四川省婦幼保健醫院藥劑科（成都 610041）;

關鍵詞：

格列美脲 2 型糖尿病有效性安全性系統評價

DOI：

10.7507/1672-2531.20090193

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　系統評價格列美脲治療2 型糖尿病的有效性及安全性。
方法　計算機檢索PubMed、Ovid（All EBM Reviews）、CNKI、萬方、維普、CBM。按Cochrane 系統評價的方法評價納入研究質量，對同質研究采用RevMan 5.0 進行Meta 分析，對數據不能合并者，則進行描述性的定性分析。
結果　本研究共納入6 個RCT 進行分析。由于納入的研究所提供的數據提供不充分，未進行合并分析。6 篇文獻質量均為B 級。研究結果顯示格列美脲組降低2 型糖尿病患者糖化血紅蛋白、空腹和餐后血糖，以及提高餐后血漿胰島素的效果與安慰劑組比較，其差異有統計學意義（P lt;0.05）。3 個研究報道格列美脲組與安慰劑組比較，對空腹血漿胰島素（FI）的影響，兩組差異有統計學意義（P lt;0.05），而1 個研究顯示兩組差異無統計學意義（P gt;0.05）。6 個RCT 結果均提示格列美脲不良反應輕微。
結論　基于當前證據，格列美脲能降低2 型糖尿病患者的糖化血紅蛋白、空腹和餐后血糖，提高空腹和餐后血漿胰島素，且不良反應輕微，是治療2 型糖尿病的有效又安全的磺脲類藥物。

引用本文： 柳汝明,賈萍,唐堯. 格列美脲治療2型糖尿病有效性及安全性系統評價. 中國循證醫學雜志, 2009, 09(10): 1094-1098. doi: 10.7507/1672-2531.20090193 復制

1.	International Diabetes Federation. Diabetes Atlas (third edition). 2007.
2.	葉任高, 陸再英. 內科學. 第6版. 北京: 人民衛生出版社, 2006, 787.
3.	吳楨, 周樹娥. 目前臨床評價最優的磺脲類降糖藥—格列美脲. 實用糖尿病雜志, 2008, 4(6): 54-55.
4.	葉任高, 陸再英. 內科學. 第6版. 北京: 人民衛生出版社, 2006, 797.
5.	American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDD-M. Diabetes Care, 1995, 18(11): 1510-1518.
6.	American Diabetes Association: Guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance (Position Statement). Diabetes Care, 1997, 20(Suppl. 1): S21.
7.	Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of Randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8.	Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2005, 27(10): 1535-1547.
9.	Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after oncedaily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care, 2004, 27(6): 1335-1342.
10.	Luis Bautista J, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized， placebo-controlled study. clinical therapeutics, 2003, 25(1): 194-209.
11.	DS Schade, L Jovanovic, J Schneider. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. the journal of Clinical Pharmacology, 1998, 38(7): 636-641.
12.	Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care, 1996, 19(11): 1194-1199.
13.	Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care, 1996, 19(8): 849-856.
14.	Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positNe results? A systematic review of controlled trials. Control Clin Trials, 1998, 19(2): 159-166.

1. International Diabetes Federation. Diabetes Atlas (third edition). 2007.
2. 葉任高, 陸再英. 內科學. 第6版. 北京: 人民衛生出版社, 2006, 787.
3. 吳楨, 周樹娥. 目前臨床評價最優的磺脲類降糖藥—格列美脲. 實用糖尿病雜志, 2008, 4(6): 54-55.
4. 葉任高, 陸再英. 內科學. 第6版. 北京: 人民衛生出版社, 2006, 797.
5. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDD-M. Diabetes Care, 1995, 18(11): 1510-1518.
6. American Diabetes Association: Guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance (Position Statement). Diabetes Care, 1997, 20(Suppl. 1): S21.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of Randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8. Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2005, 27(10): 1535-1547.
9. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after oncedaily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care, 2004, 27(6): 1335-1342.
10. Luis Bautista J, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized， placebo-controlled study. clinical therapeutics, 2003, 25(1): 194-209.
11. DS Schade, L Jovanovic, J Schneider. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. the journal of Clinical Pharmacology, 1998, 38(7): 636-641.
12. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care, 1996, 19(11): 1194-1199.
13. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care, 1996, 19(8): 849-856.
14. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positNe results? A systematic review of controlled trials. Control Clin Trials, 1998, 19(2): 159-166.

上一篇
丹紅注射液治療糖尿病腎病的系統評價
下一篇
燈盞細辛治療糖尿病腎病的系統評價

《中國循證醫學雜志》

格列美脲治療2型糖尿病有效性及安全性系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

格列美脲治療2型糖尿病有效性及安全性系統評價

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料